Sidgiddi S, Ranganathan U, Gautam A. DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application. J of Skin [Internet]. 2017 Oct. 27 [cited 2024 Jul. 23];1(3.1):s46. Available from: https://jofskin.org/33014/index.php/skin/article/view/199